Gemina Laboratories Ltd. (GLAB) AI Stock Analysis

• Market Cap: C$32.93M
• Dividend Yield: N/A
• Average Volume (3M): 8.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.20
• Revenue Growth: N/A
• EPS Growth: 9.12%
• Country: CA
• Employees: 6
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 76,570,910
• 10 Day Avg. Volume: 7,676
• 30 Day Avg. Volume: 8,608
• PEG Ratio: 0.42
• Price to Book (P/B): -9.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -30.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 35 Underperform
• Price Target: ―

Gemina Laboratories Ltd.'s overall stock score is primarily impacted by its precarious financial position, characterized by significant losses and cash flow challenges. The technical analysis shows some positive momentum, providing a glimmer of short-term optimism, but the overbought RSI suggests caution. Valuation metrics remain concerning, with a negative P/E ratio highlighting the financial challenges. These factors collectively suggest a high-risk profile for the stock.

Gemina Laboratories Ltd. Business Overview & Revenue Model

Company Description

Gemina Laboratories Ltd. (GLAB) is a biotechnology company that operates in the healthcare sector. The company specializes in the development of next-generation diagnostic tests that leverage advanced proprietary technology. Gemina's core products include innovative diagnostic solutions designed to provide rapid, accurate, and cost-effective testing for a variety of diseases and health conditions.

How the Company Makes Money

Gemina Laboratories Ltd. generates revenue primarily through the sale of its diagnostic products to healthcare providers, laboratories, and other medical institutions. The company may also engage in partnerships and collaborations with other biotechnology firms and research institutions to enhance the development and distribution of its products. Licensing its proprietary technology to other companies for use in their diagnostic solutions could serve as an additional revenue stream. Furthermore, Gemina might receive funding or grants from governmental or non-governmental organizations interested in promoting advanced healthcare solutions.

Gemina Laboratories Ltd. Financial Statement Overview

Summary

Gemina Laboratories Ltd. is in a precarious financial position, characterized by a lack of revenue, consistent losses, and a high reliance on external financing to sustain operations. The negative equity and cash flow challenges highlight the need for strategic pivots to improve financial health and stability in the highly competitive biotechnology industry.

Income Statement

Gemina Laboratories Ltd. currently reports no revenue, which is a significant challenge for the company's financial health. The company shows consistent losses with negative net income and EBIT, indicating difficulties in achieving profitability. This trend highlights the need for a viable revenue model or cost management strategies to improve financial performance.

Balance Sheet

The company's balance sheet reflects a negative stockholders' equity, suggesting financial distress and a high debt burden relative to its assets. The debt-to-equity ratio cannot be calculated due to negative equity, but the high liabilities in comparison to assets indicate potential solvency risks. Improving equity structure and asset base is crucial for long-term sustainability.

Cash Flow

Gemina Laboratories faces negative operating and free cash flows, indicating challenges in generating cash from operations. The company relies heavily on financing to cover operational deficits. This reliance could pose risks if external financing becomes less accessible, emphasizing the need for improving cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.88K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-45.33K	-113.24K	-93.37K	-50.28K	-43.83K	-12.09K
EBITDA	-3.72M	-3.80M	-5.18M	-5.93M	-4.69M	-819.60K
Net Income	-4.01M	-4.07M	-5.22M	-5.98M	-4.74M	-834.15K
Balance Sheet
Total Assets	1.19M	1.44M	1.46M	1.87M	1.42M	2.53M
Cash, Cash Equivalents and Short-Term Investments	14.97K	703.00	990.00	83.09K	1.17M	898.05K
Total Debt	243.65K	1.27M	485.33K	240.84K	46.08K	98.13K
Total Liabilities	5.58M	5.87M	3.04M	1.95M	475.92K	2.37M
Stockholders Equity	-4.39M	-4.44M	-1.59M	-71.81K	944.23K	159.96K
Cash Flow
Free Cash Flow	-465.26K	-1.30M	-3.29M	-4.59M	-3.88M	-319.09K
Operating Cash Flow	-465.26K	-1.30M	-3.24M	-4.51M	-3.87M	-319.09K
Investing Cash Flow	18.42K	18.42K	-41.35K	-505.07K	8.20K	13.91K
Financing Cash Flow	460.15K	1.28M	3.20M	3.94M	4.14M	2.72M

Gemina Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GLAB, the sentiment is Negative. The current price of 0.32 is below the 20-day moving average (MA) of 0.50, below the 50-day MA of 0.63, and below the 200-day MA of 0.80, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 27.25 is Positive, neither overbought nor oversold. The STOCH value of 14.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GLAB.

Gemina Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	74 Outperform	C$63.06M	27.01	9.01%	―	13.00%	―
MBX	57 Neutral	C$32.21M	24.14	-1.13%	―	-9.54%	-105.12%
Sector *	51 Neutral	$7.93B	-0.32	-43.43%	2.21%	22.30%	-1.88%
GLAB	35 Underperform	C$32.93M	―	98.62%	―	―	9.12%
ONCY	―	$129.60M	―	-244.84%	―	―	―
MIR	41 Neutral	C$54.42M	―		―	-33.66%	-48.89%
SVA	33 Underperform	C$59.13M	―	248.46%	―	―	49.34%